Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.
about
Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitroAn Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014Prodrugs of phosphonates and phosphates: crossing the membrane barrierPhase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.Emerging antivirals for the treatment of hepatitis B.A cutting-edge view on the current state of antiviral drug development.Acyclic nucleoside phosphonates: a key class of antiviral drugs.Inhibition of CatA: an emerging strategy for the treatment of heart failure.Comparative biophysical properties of tenofovir-loaded, thiolated and nonthiolated chitosan nanoparticles intended for HIV preventionRole of cathepsin A and lysosomes in the intracellular activation of novel antipapillomavirus agent GS-9191.Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.Advances in Nucleotide Antiviral Development from Scientific Discovery to Clinical Applications: Tenofovir Disoproxil Fumarate for Hepatitis B.Pre-steady state kinetic analysis of cyclobutyl derivatives of 2'-deoxyadenosine 5'-triphosphate as inhibitors of HIV-1 reverse transcriptase.pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmissionFormulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention.In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.Adenine: an important drug scaffold for the design of antiviral agentsPhysiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyPractical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.Tenofovir and bone health.Overcoming pharmacologic sanctuaries.A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure ProphylaxisSpray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres intended for HIV prevention.Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug ResistanceThe efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography.Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?The acyclic nucleoside phosphonates (ANPs): Antonín Holý's legacy.Anti-HIV Nucleoside Phosphonate GS-9148 and Its Prodrug GS-9131: Scale Up of a 2'-F Modified Cyclic Nucleoside Phosphonate and Synthesis of Selected Amidate Prodrugs.Darunavir/cobicistat once daily for the treatment of HIV.
P2860
Q24633870-493CAC35-16DF-4000-9B80-1D45AA28C629Q26771734-259E3A7E-5E9D-4442-928E-380E1276E0A9Q27005712-32FC390E-6775-4AC2-AE7B-CA5D7D933E14Q33460754-AF106697-602D-47A6-8F78-5E6D701F3305Q33801328-1152553B-4133-4486-9B33-FDE5AD7420BFQ34036018-F7125BD6-335B-4B82-B5DA-92A0EB81A837Q34464655-172B3F0A-A4CC-405A-A38E-A5B62D983F5DQ34621201-FD8279E5-BCF0-437B-B04E-7507CEA6DFA3Q34784522-B5E496CE-EFDD-4919-A528-E92F643C8EBAQ34932426-FA3F9C37-A4B9-40E6-A801-5E79A127988CQ35077568-346A3D79-3D0C-430B-8CF4-65F7B17E2279Q35746114-1814F0C6-C93E-4905-98A1-E96DDE2241BDQ35906015-A7AF4D65-1BB2-4B8C-A395-0358222D8562Q35996025-1E3C662E-A5DE-41C2-ABDE-5CB12ADADBD5Q36032459-60BC1CE2-6DA1-4BF7-A49E-0A2897B800A1Q36032471-DD7D9845-5A07-4A86-A1BB-8F0E58D63A0FQ36075908-3489B4C7-809B-4294-B52E-56E156E95D6DQ36076011-48C72AAE-3153-40B0-9A89-616ADF2A5FADQ36172455-0293FF10-7B6E-4485-BB14-3A2B720D96E7Q36238668-C992DC40-05E1-4684-9AA2-F7D1F2881282Q36243626-51C7F9E5-697F-400B-8363-8F769409E097Q36275141-C622477A-B004-4C06-87C2-2C45004A2605Q36276790-8077DD7F-0CC8-4034-9C24-63D0F2207F94Q36425068-BD0653F9-F511-4745-90B6-05CAA4B176B7Q36706781-D20918F1-C4EB-4145-B2F7-33BDF328A3F5Q36721012-7C8D044A-9B25-4D39-8F69-6E76B8DC9777Q36727960-27406FFD-A33A-46EB-AB52-C7964B2D56BBQ36833961-18742926-CCC2-455F-9AF4-B31C779DF2C5Q36915933-8F0DA250-29AE-4EFD-BAAE-B8C14312F84CQ36968405-8526D958-CED0-4177-962E-460A52ABCA72Q37157173-B9192E9F-E7C4-4ECA-A0BA-56647502A610Q37263395-26E33625-E488-4F87-8817-211EA0A3BDD9Q37288671-8C6407DC-A3DC-4CF3-8EBE-A68693885CE0Q37354871-86532DB0-ADFE-4F9A-9492-157A5E954FA0Q37392720-3910056E-9F89-43A9-BB23-401B1C6A56B2Q37421891-8CE087F5-D832-4477-AFEB-97239D2A6313Q38009758-5BE73C1F-A68B-4122-8C2A-44B19825F34AQ38097391-9B80C47A-8978-4232-B5F6-D884D100A084Q38326708-499E3470-3944-44EF-91EE-3D1CDD1867FFQ38472696-8CC35E11-E906-41FC-B2AE-8F4819D06B09
P2860
Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Selective intracellular activa ...... umulation in lymphatic tissue.
@ast
Selective intracellular activa ...... umulation in lymphatic tissue.
@en
type
label
Selective intracellular activa ...... umulation in lymphatic tissue.
@ast
Selective intracellular activa ...... umulation in lymphatic tissue.
@en
prefLabel
Selective intracellular activa ...... umulation in lymphatic tissue.
@ast
Selective intracellular activa ...... umulation in lymphatic tissue.
@en
P2093
P2860
P1476
Selective intracellular activa ...... umulation in lymphatic tissue.
@en
P2093
Andrew Mulato
Eugene Eisenberg
Gong-Xin He
Kenneth C Cundy
Swami Swaminathan
William A Lee
P2860
P304
P356
10.1128/AAC.49.5.1898-1906.2005
P407
P50
P577
2005-05-01T00:00:00Z